Dr. Reddy: 2Q PAT down 31% - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy: 2Q PAT down 31%

Oct 24, 2002

Dr. Reddy's, after reporting solid growth over the past year, has registered a decline in turnover. The drop in sales is primarily due to slowdown in fluoxetine sales, which has reflected across the income statement. The company has continued to show good growth in active pharma ingredients (API) business and branded formulations.

(Rs m)2QFY022QFY03Change1HFY021HFY03Change
Net Sales 4,739 4,037 -14.8% 7,375 7,387 0.2%
Other Income 204 167 -17.9% 290 334 15.2%
Expenditure 2,298 2,934 27.7% 4,280 5,346 24.9%
Operating Profit (EBDIT) 2,442 1,103 -54.8% 3,096 2,042 -34.1%
Operating Profit Margin (%)51.5%27.3% 42.0%27.6% 
Interest 14 13 -8.4% 64 27 -58.1%
Depreciation 122 144 18.6% 234 281 20.0%
Profit before Tax 2,510 1,114 -55.6% 3,087 2,068 -33.0%
Extraordinary income (1,083) -   (1,083) -  
Tax (8) 122 -1677.9% 35 274 694.5%
Profit after Tax/(Loss) 1,434 992 -30.8% 1,969 1,793 -8.9%
Net profit margin (%)30.3%24.6% 26.7%24.3% 
No. of Shares (eoy) (m) 38.3 76.5   38.3 76.5  
Fully Diluted Earnings per share* 75.0 51.9   51.5 46.9  
P/E Ratio     15.5  

In our earlier reports, we had indicated that sales from fluoxetine business are expected to decline. Adjusting for the same, sales in the half-year period have increased by 22% YoY. The API business is likely to have continued to performed well on the back of Tizanidine and Doxazosin. API exports are expected to catapult in the future considering the fact that the company has filed 3 DMF's (Drug Master Filings) in 4QFY02 and is likely to have made more filings last quarter.

In branded formulations, the company reported a overall 14% growth including both domestic and international business. The growth in the domestic market could have been facilitated by dental products. It may be recalled that the company acquired 6 dental brands in India from a local Indian company (Groupe Pharma) last year, which has added to domestic formulations sales in the current year.

As mentioned earlier, financials are reflecting the effect of decline in fluoxetine sales. Marketing exclusivity for fluoxetine expired in January '02 leading to sharp price erosion (almost 80%), as two other competitors have entered the market. That said, with revenues from new businesses supporting organisational expansion and increased R&D expense, a similar buffer has not been present in quarter ended September '02 leading to drop in margins. R&D expense for the quarter has almost doubled from 4.5% to 8.6% of net sales.

At Rs 726, the scrip is trading on a multiple of 15.5x 1HFY03 annualised stand-alone earnings, as compared to 20.2x 1QFY03 annualised stand-alone earnings. It may be recalled that the company received a major setback in 2Q with suspension of clinical trials for the outlicensed anti-diabetic molecule (Ragaglitazar). Also, there were concerns that the company delayed disclosing the Ragaglitazar setback. We had mentioned that moving towards a research oriented business model could lead to lumpiness in earnings before a steady drug pipeline is built.

Equitymaster requests your view! Post a comment on "Dr. Reddy: 2Q PAT down 31%". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 30, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS